CAR-T trial for blood cancer halted after single patient
NCT ID NCT06068400
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new CAR-T cell therapy for people with multiple myeloma that had come back or stopped responding to treatment. The therapy uses a patient's own immune cells to target cancer cells. The trial was stopped early and only enrolled one person, so we have very limited information about its safety or effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Qianhai Shekou Free Trade Zone Hospital
Shenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding selinexor to standard therapy extend remission in Hard-to-Treat myeloma?
- Can a new drug combo outsmart Hard-to-Treat myeloma?
- Engineered immune cells take on Hard-to-Treat myeloma
- Home infusion for myeloma drug passes early safety check
- New hope for multiple myeloma: phase 3 trial launches
- New CAR T-Cell therapy targets Hard-to-Treat myeloma